These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 23624566)

  • 1. Characterization of the Huntington intermediate CAG repeat expansion phenotype in PHAROS.
    Killoran A; Biglan KM; Jankovic J; Eberly S; Kayson E; Oakes D; Young AB; Shoulson I
    Neurology; 2013 May; 80(22):2022-7. PubMed ID: 23624566
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical-Genetic Associations in the Prospective Huntington at Risk Observational Study (PHAROS): Implications for Clinical Trials.
    ; Biglan KM; Shoulson I; Kieburtz K; Oakes D; Kayson E; Shinaman MA; Zhao H; Romer M; Young A; Hersch S; Penney J; Marder K; Paulsen J; Quaid K; Siemers E; Tanner C; Mallonee W; Suter G; Dubinsky R; Gray C; Nance M; Bundlie S; Radtke D; Kostyk S; Baic C; Caress J; Walker F; Hunt V; O'Neill C; Chouinard S; Factor S; Greenamyre T; Wood-Siverio C; Corey-Bloom J; Song D; Peavy G; Moskowitz C; Wesson M; Samii A; Bird T; Lipe H; Blindauer K; Marshall F; Zimmerman C; Goldstein J; Rosas D; Novak P; Caviness J; Adler C; Duffy A; Wheelock V; Tempkin T; Richman D; Seeberger L; Albin R; Chou KL; Racette B; Perlmutter JS; Perlman S; Bordelon Y; Martin W; Wieler M; Leavitt B; Raymond L; Decolongon J; Clarke L; Jankovic J; Hunter C; Hauser RA; Sanchez-Ramos J; Furtado S; Suchowersky O; Klimek ML; Guttman M; Sethna R; Feigin A; Cox M; Shannon B; Percy A; Dure L; Harrison M; Johnson W; Higgins D; Molho E; Nickerson C; Evans S; Hobson D; Singer C; Galvez-Jimenez N; Shannon K; Comella C; Ross C; Saint-Hilaire MH; Testa C; Rosenblatt A; Hogarth P; Weiner W; Como P; Kumar R; Cotto C; Stout J; Brocht A; Watts A; Eberly S; Weaver C; Foroud T; Gusella J; MacDonald M; Myers R; Fahn S; Shults C
    JAMA Neurol; 2016 Jan; 73(1):102-10. PubMed ID: 26569098
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical manifestations of intermediate allele carriers in Huntington disease.
    Cubo E; Ramos-Arroyo MA; Martinez-Horta S; Martínez-Descalls A; Calvo S; Gil-Polo C;
    Neurology; 2016 Aug; 87(6):571-8. PubMed ID: 27402890
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Huntington's disease: how intermediate are intermediate repeat lengths?
    Squitieri F; Jankovic J
    Mov Disord; 2012 Dec; 27(14):1714-7. PubMed ID: 23008174
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Weight loss in Huntington disease increases with higher CAG repeat number.
    Aziz NA; van der Burg JM; Landwehrmeyer GB; Brundin P; Stijnen T; ; Roos RA
    Neurology; 2008 Nov; 71(19):1506-13. PubMed ID: 18981372
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Factors related to genetic testing in adults at risk for Huntington disease: the prospective Huntington at-risk observational study (PHAROS).
    Quaid KA; Eberly SW; Kayson-Rubin E; Oakes D; Shoulson I;
    Clin Genet; 2017 Jun; 91(6):824-831. PubMed ID: 27740685
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Is There Convincing Evidence that Intermediate Repeats in the HTT Gene Cause Huntington's Disease?
    Oosterloo M; Van Belzen MJ; Bijlsma EK; Roos RA
    J Huntingtons Dis; 2015; 4(2):141-8. PubMed ID: 26397895
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A critical window of CAG repeat-length correlates with phenotype severity in the R6/2 mouse model of Huntington's disease.
    Cummings DM; Alaghband Y; Hickey MA; Joshi PR; Hong SC; Zhu C; Ando TK; André VM; Cepeda C; Watson JB; Levine MS
    J Neurophysiol; 2012 Jan; 107(2):677-91. PubMed ID: 22072510
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical correlates of mitochondrial function in Huntington's disease muscle.
    Turner C; Cooper JM; Schapira AH
    Mov Disord; 2007 Sep; 22(12):1715-21. PubMed ID: 17557337
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relationship of Mediterranean diet and caloric intake to phenoconversion in Huntington disease.
    Marder K; Gu Y; Eberly S; Tanner CM; Scarmeas N; Oakes D; Shoulson I;
    JAMA Neurol; 2013 Nov; 70(11):1382-8. PubMed ID: 24000094
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Exploring the correlates of intermediate CAG repeats in Huntington disease.
    Ha AD; Jankovic J
    Postgrad Med; 2011 Sep; 123(5):116-21. PubMed ID: 21904093
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical phenotype in carriers of intermediate alleles in the huntingtin gene.
    Savitt D; Jankovic J
    J Neurol Sci; 2019 Jul; 402():57-61. PubMed ID: 31103960
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transgenic mice expressing mutated full-length HD cDNA: a paradigm for locomotor changes and selective neuronal loss in Huntington's disease.
    Reddy PH; Charles V; Williams M; Miller G; Whetsell WO; Tagle DA
    Philos Trans R Soc Lond B Biol Sci; 1999 Jun; 354(1386):1035-45. PubMed ID: 10434303
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Factors influencing the clinical expression of intermediate CAG repeat length mutations of the Huntington's disease gene.
    Panegyres PK; Shu CC; Chen HY; Paulsen JS
    J Neurol; 2015 Feb; 262(2):277-84. PubMed ID: 25380582
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of a large group of individuals with huntington disease and their relatives enrolled in the COHORT study.
    ; Dorsey E
    PLoS One; 2012; 7(2):e29522. PubMed ID: 22359536
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of CAG Repeat Length in the Huntington Gene With Cognitive Performance in Young Adults.
    Schultz JL; Saft C; Nopoulos PC
    Neurology; 2021 May; 96(19):e2407-e2413. PubMed ID: 33692166
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical and genetic characteristics in patients with Huntington's disease from China.
    Yang J; Chen K; Wei Q; Chen Y; Cao B; Burgunder JM; Shang HF
    Neurol Res; 2016 Oct; 38(10):916-20. PubMed ID: 27483361
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Autopsy-proven Huntington's disease with 29 trinucleotide repeats.
    Kenney C; Powell S; Jankovic J
    Mov Disord; 2007 Jan; 22(1):127-30. PubMed ID: 17115386
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Late-onset Huntington disease with intermediate CAG repeats: true or false?
    Groen JL; de Bie RM; Foncke EM; Roos RA; Leenders KL; Tijssen MA
    J Neurol Neurosurg Psychiatry; 2010 Feb; 81(2):228-30. PubMed ID: 20145031
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A new mutation for Huntington disease following maternal transmission of an intermediate allele.
    Semaka A; Kay C; Belfroid RD; Bijlsma EK; Losekoot M; van Langen IM; van Maarle MC; Oosterloo M; Hayden MR; van Belzen MJ
    Eur J Med Genet; 2015 Jan; 58(1):28-30. PubMed ID: 25464109
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.